Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

Carla Giordano, Felicia Pant, Maria P. Amato, Nunzia Sapienza, Alberto Pugliese, Aldo Galluzzo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels ≤7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy and within 5 weeks of onset of symptoms, were treated with intravenous (i.v.) thymopoietin32-36 pentapeptide (Thy) (1 mg/kg/body weight) for 7 days and twice per week for up to 3 months. A control IDDM group without initial significant differences in metabolic control parameters was also studied. No difference was observed between the two IDDM groups regarding the after-diagnosis normalization curve of HbA1c; mean daily glycemic level rates and ICA titer decreased during the observation. A reduction in anti-insulin anti-bodies (AIA) in Thy-treated patients was observed in comparison to conventionally treated IDDM starting from 6 months and reaching a reduction peak at 1 year (P≤0.02). As regards the NIR remission rate, it was significantly more accelerated in Thy-treated patients, reaching 43% at 6 months and 57% at 1 year vs 12% and 6.7% respectively in the control IDDM group (P range ≤0.05-0.02). Insulin requirement/kg/bodyweight was progressively significantly reduced in Thy-treated patients during the observation period (P range ≤0.01-0.001). Tac-positive cells and serum soluble interleukin-2 receptors (s IL2R) were significantly reduced in Thy-treated patients starting from 3 months, with a striking difference with respect to controls, which began after 6 months. Thy administration, known to enhance cell-mediated immunity, might increase NIR remission periods in very recently diagnosed IDDM patients, probably by inducing T-suppressor cell recruitment. This hypothesis is strongly suggested by the decrease in AIA production and IL 2 R levels in Thy-treated patients, which seem to be the main characteristics of their immunological pattern.

Original languageEnglish
Pages (from-to)611-617
Number of pages7
JournalJournal of Autoimmunity
Volume3
Issue number5
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Remission Induction
Immunologic Factors
Type 1 Diabetes Mellitus
Insulin
Thymopentin
Observation
Control Groups
Breakfast
C-Peptide
Interleukin-2 Receptors
Cellular Immunity
Interleukin-2
Meals
Blood Glucose
Body Weight
Clinical Trials

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. / Giordano, Carla; Pant, Felicia; Amato, Maria P.; Sapienza, Nunzia; Pugliese, Alberto; Galluzzo, Aldo.

In: Journal of Autoimmunity, Vol. 3, No. 5, 01.01.1990, p. 611-617.

Research output: Contribution to journalArticle

Giordano, Carla ; Pant, Felicia ; Amato, Maria P. ; Sapienza, Nunzia ; Pugliese, Alberto ; Galluzzo, Aldo. / Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. In: Journal of Autoimmunity. 1990 ; Vol. 3, No. 5. pp. 611-617.
@article{4db16c48628242ec874d0081f38d8bd0,
title = "Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus",
abstract = "A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels ≤7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy and within 5 weeks of onset of symptoms, were treated with intravenous (i.v.) thymopoietin32-36 pentapeptide (Thy) (1 mg/kg/body weight) for 7 days and twice per week for up to 3 months. A control IDDM group without initial significant differences in metabolic control parameters was also studied. No difference was observed between the two IDDM groups regarding the after-diagnosis normalization curve of HbA1c; mean daily glycemic level rates and ICA titer decreased during the observation. A reduction in anti-insulin anti-bodies (AIA) in Thy-treated patients was observed in comparison to conventionally treated IDDM starting from 6 months and reaching a reduction peak at 1 year (P≤0.02). As regards the NIR remission rate, it was significantly more accelerated in Thy-treated patients, reaching 43{\%} at 6 months and 57{\%} at 1 year vs 12{\%} and 6.7{\%} respectively in the control IDDM group (P range ≤0.05-0.02). Insulin requirement/kg/bodyweight was progressively significantly reduced in Thy-treated patients during the observation period (P range ≤0.01-0.001). Tac-positive cells and serum soluble interleukin-2 receptors (s IL2R) were significantly reduced in Thy-treated patients starting from 3 months, with a striking difference with respect to controls, which began after 6 months. Thy administration, known to enhance cell-mediated immunity, might increase NIR remission periods in very recently diagnosed IDDM patients, probably by inducing T-suppressor cell recruitment. This hypothesis is strongly suggested by the decrease in AIA production and IL 2 R levels in Thy-treated patients, which seem to be the main characteristics of their immunological pattern.",
author = "Carla Giordano and Felicia Pant and Amato, {Maria P.} and Nunzia Sapienza and Alberto Pugliese and Aldo Galluzzo",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/S0896-8411(05)80028-9",
language = "English",
volume = "3",
pages = "611--617",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

AU - Giordano, Carla

AU - Pant, Felicia

AU - Amato, Maria P.

AU - Sapienza, Nunzia

AU - Pugliese, Alberto

AU - Galluzzo, Aldo

PY - 1990/1/1

Y1 - 1990/1/1

N2 - A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels ≤7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy and within 5 weeks of onset of symptoms, were treated with intravenous (i.v.) thymopoietin32-36 pentapeptide (Thy) (1 mg/kg/body weight) for 7 days and twice per week for up to 3 months. A control IDDM group without initial significant differences in metabolic control parameters was also studied. No difference was observed between the two IDDM groups regarding the after-diagnosis normalization curve of HbA1c; mean daily glycemic level rates and ICA titer decreased during the observation. A reduction in anti-insulin anti-bodies (AIA) in Thy-treated patients was observed in comparison to conventionally treated IDDM starting from 6 months and reaching a reduction peak at 1 year (P≤0.02). As regards the NIR remission rate, it was significantly more accelerated in Thy-treated patients, reaching 43% at 6 months and 57% at 1 year vs 12% and 6.7% respectively in the control IDDM group (P range ≤0.05-0.02). Insulin requirement/kg/bodyweight was progressively significantly reduced in Thy-treated patients during the observation period (P range ≤0.01-0.001). Tac-positive cells and serum soluble interleukin-2 receptors (s IL2R) were significantly reduced in Thy-treated patients starting from 3 months, with a striking difference with respect to controls, which began after 6 months. Thy administration, known to enhance cell-mediated immunity, might increase NIR remission periods in very recently diagnosed IDDM patients, probably by inducing T-suppressor cell recruitment. This hypothesis is strongly suggested by the decrease in AIA production and IL 2 R levels in Thy-treated patients, which seem to be the main characteristics of their immunological pattern.

AB - A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels ≤7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy and within 5 weeks of onset of symptoms, were treated with intravenous (i.v.) thymopoietin32-36 pentapeptide (Thy) (1 mg/kg/body weight) for 7 days and twice per week for up to 3 months. A control IDDM group without initial significant differences in metabolic control parameters was also studied. No difference was observed between the two IDDM groups regarding the after-diagnosis normalization curve of HbA1c; mean daily glycemic level rates and ICA titer decreased during the observation. A reduction in anti-insulin anti-bodies (AIA) in Thy-treated patients was observed in comparison to conventionally treated IDDM starting from 6 months and reaching a reduction peak at 1 year (P≤0.02). As regards the NIR remission rate, it was significantly more accelerated in Thy-treated patients, reaching 43% at 6 months and 57% at 1 year vs 12% and 6.7% respectively in the control IDDM group (P range ≤0.05-0.02). Insulin requirement/kg/bodyweight was progressively significantly reduced in Thy-treated patients during the observation period (P range ≤0.01-0.001). Tac-positive cells and serum soluble interleukin-2 receptors (s IL2R) were significantly reduced in Thy-treated patients starting from 3 months, with a striking difference with respect to controls, which began after 6 months. Thy administration, known to enhance cell-mediated immunity, might increase NIR remission periods in very recently diagnosed IDDM patients, probably by inducing T-suppressor cell recruitment. This hypothesis is strongly suggested by the decrease in AIA production and IL 2 R levels in Thy-treated patients, which seem to be the main characteristics of their immunological pattern.

UR - http://www.scopus.com/inward/record.url?scp=0025165454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025165454&partnerID=8YFLogxK

U2 - 10.1016/S0896-8411(05)80028-9

DO - 10.1016/S0896-8411(05)80028-9

M3 - Article

C2 - 2252529

AN - SCOPUS:0025165454

VL - 3

SP - 611

EP - 617

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 5

ER -